[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1105179T1 - Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων - Google Patents

Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων

Info

Publication number
CY1105179T1
CY1105179T1 CY20061101216T CY061101216T CY1105179T1 CY 1105179 T1 CY1105179 T1 CY 1105179T1 CY 20061101216 T CY20061101216 T CY 20061101216T CY 061101216 T CY061101216 T CY 061101216T CY 1105179 T1 CY1105179 T1 CY 1105179T1
Authority
CY
Cyprus
Prior art keywords
drugs
malignant tumors
immune treatment
tumors
immune
Prior art date
Application number
CY20061101216T
Other languages
English (en)
Inventor
Claudia Ulbrich
Klaus-Dieter ROCKENSÜSS
Armin Grossmann
Original Assignee
Liponova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Ag filed Critical Liponova Ag
Publication of CY1105179T1 publication Critical patent/CY1105179T1/el

Links

Classifications

    • A61K39/4615—
    • A61K39/4622—
    • A61K39/4644—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Περιεχόμενο της παρούσας εφεύρεσης είναι μια σύνθεση, η οποία μπορεί να χρησιμοποιείται σαν φάρμακο ή για την παρασκευή ενός φαρμάκου για την ανοσοθεραπεία όγκων ή για τον εμβολιασμό όγκων. Η εφεύρεση περιλαμβάνει επίσης μεθόδους για την παρασκευή φαρμάκων για την ανοσοθεραπεία όγκων ή για τον εμβολιασμό όγκων.
CY20061101216T 2000-07-28 2006-08-29 Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων CY1105179T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren
EP01958002A EP1305041B1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (1)

Publication Number Publication Date
CY1105179T1 true CY1105179T1 (el) 2010-03-03

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101216T CY1105179T1 (el) 2000-07-28 2006-08-29 Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων

Country Status (20)

Country Link
US (2) US20030129206A1 (el)
EP (1) EP1305041B1 (el)
JP (1) JP2004505058A (el)
AT (1) ATE330626T1 (el)
AU (1) AU2001279775A1 (el)
BG (1) BG107482A (el)
CA (1) CA2417374A1 (el)
CY (1) CY1105179T1 (el)
CZ (1) CZ299669B6 (el)
DE (1) DE50110274D1 (el)
DK (1) DK1305041T3 (el)
ES (1) ES2267800T3 (el)
HK (1) HK1055562A1 (el)
HU (1) HUP0300772A3 (el)
NO (1) NO20030420L (el)
PL (1) PL358675A1 (el)
PT (1) PT1305041E (el)
SI (1) SI1305041T1 (el)
SK (1) SK822003A3 (el)
WO (1) WO2002009745A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
CN1764375A (zh) * 2003-02-20 2006-04-26 康涅狄格大学健康中心 使用包括热休克蛋白或α－2－巨球蛋白的组合物治疗癌症和传染病的方法
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
BRPI1013957A2 (pt) 2009-07-02 2016-04-05 Ith Immune Therapy Holdings Ab método para produzir exossomas moduladores imunes específicos, composição farmacêutica, exossoma, e, método para tratar um indivíduo em necessidade do tratamento.
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
EP3425400B1 (en) 2017-07-05 2022-01-26 VCC Medical Deutschland GmbH Method for manufacturing a tumor vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
DE69939821D1 (de) * 1998-04-02 2008-12-11 Univ California Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
US20030129206A1 (en) 2003-07-10
EP1305041B1 (de) 2006-06-21
HUP0300772A2 (en) 2003-08-28
EP1305041A1 (de) 2003-05-02
CA2417374A1 (en) 2003-01-27
ES2267800T3 (es) 2007-03-16
PL358675A1 (en) 2004-08-09
CZ2003179A3 (cs) 2004-01-14
US20070134275A1 (en) 2007-06-14
CZ299669B6 (cs) 2008-10-08
NO20030420D0 (no) 2003-01-27
DK1305041T3 (da) 2006-10-23
SK822003A3 (en) 2004-05-04
WO2002009745A1 (de) 2002-02-07
DE50110274D1 (de) 2006-08-03
ATE330626T1 (de) 2006-07-15
JP2004505058A (ja) 2004-02-19
AU2001279775A1 (en) 2002-02-13
HUP0300772A3 (en) 2005-11-28
PT1305041E (pt) 2006-09-29
NO20030420L (no) 2003-01-27
SI1305041T1 (sl) 2006-12-31
BG107482A (bg) 2003-11-28
HK1055562A1 (en) 2004-01-16

Similar Documents

Publication Publication Date Title
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
SE0002320D0 (sv) Malignant tumors
SI1255537T1 (sl) Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
HUP0204216A2 (en) A new use of antibodies as vaccines
DK0522078T3 (da) GP75 som en tumorvaccine mod melanom
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
TNSN07187A1 (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. their use in the treatment of cancer
MY141122A (en) Vaccine composition containing transforming growth factor alpha (tgf[alpha]). it use in malignant diseases therapy
MD3616706T2 (ro) Noi peptide și combinație de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și a altor cancere
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
MX2024002187A (es) Anticuerpos y conjugados de nectina-4.
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
WO2001048205A3 (en) Murine neu sequences and methods of use therefor
CY1111320T1 (el) Cripto ειδικα αντισωματα